TRANSPARENCY COMMITTEE OPINION. 19 July 2006
|
|
- Alan Fisher
- 6 years ago
- Views:
Transcription
1 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: ) Keppra 500 mg, film-coated tablets Box of 60 tablets (CIP code: ) Keppra 1000 mg, film-coated tablets Box of 60 tablets (CIP code: ) Keppra 100 mg/ml oral solution Vial containing 300 ml (CIP code: ) Keppra 100 mg/ml concentrate for infusion Vial containing 5 ml, box of 10 vials (CIP: ) Applicant: UCB SA levetiracetam list I Dates of Marketing Authorisations: Keppra 250 mg, 500 mg, 1000 mg film-coated tablets: 29 September 2000 Keppra 100 mg/ml oral solution: 03 March 2003 Keppra 100 mg/ml concentrate for infusion: 29 March 2006 Date of amendment of Marketing Authorisation: Keppra 250 mg, 500 mg, 1000 mg film-coated tablets, and Keppra 100 mg/ml oral solution: 13 September 2005 (Extension of indication to children from the age of 4 years). Reason for request: Keppra 250 mg, 500 mg, 1000 mg film-coated tablets: inclusion on the list of drugs reimbursed by National Insurance and approved for hospital use in the extension of indication children from the age of 4 years". Keppra 100 mg/ml oral solution: inclusion on the list of drugs reimbursed by National Insurance and approved for hospital use Keppra 100 mg/ml concentrate for infusion: inclusion on the list of drugs approved for hospital use Health Technology Assessment Division 1
2 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient levetiracetam 1.2. Background Not an original product 1.3. Indication Keppra is indicated as add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. Keppra concentrate for infusion is an alternative for patients when they are temporarily unable to take the oral form Dosage The total daily dose should be divided into two equal doses. Conversion between oral and intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained. Keppra concentrate for infusion is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion. There is no experience with administration of intravenous levetiracetam for a longer period than 4 days. Adults ( 18 years) and adolescents (12 17 years) weighting 50 kg or more The initial therapeutic dose is 500 mg twice daily. This dose may be given right from the start of treatment. The daily dose may be increased up to 1500 mg twice daily, depending on clinical response. Any increase or decrease in the dose should be made in steps of 500 mg twice daily every 2 4 weeks. Elderly subjects (65 years and older) Adjustment of the dose is recommended in elderly patients with impaired renal function (see SPC). Children aged 4 11 years and adolescents (12 17 years) weighing less than 50 kg The initial therapeutic dose is 10 mg twice daily. The daily dose may be increased up to 30 mg twice daily, depending on clinical response and tolerability. The dose should not be increased or decreased in steps of more than 10 mg/kg twice daily every two weeks. The lowest effective dose should be used. Dosage in children 50 kg or greater is the same as in adults. Doctors should prescribe the most appropriate pharmaceutical form and strength according to weight and dose. 2
3 Dosage recommendations for children and adolescents Initial (10 mg/kg 2x/day) and maximum (30 mg/kg 2x/day) doses Weight (kg) Initial Dose (mg twice daily) Maximum 15 (1) (1) From 50 (2) (1) Children 20 kg or less should preferably start treatment with Keppra 100 mg/ml oral solution (2) Dosage in children and adolescents 50 kg or greater is the same as in adults. The graduated syringe for the oral form contains up to 1000 mg of levetiracetam (corresponding to 10 ml) with a graduation every 25 mg (corresponding to 0.25 ml). A Keppra concentrate vial contains 500 mg of levetiracetam in 5 ml (corresponding to 100 mg/ml). Children under 4 years: Keppra is not recommended due to insufficient data on efficacy and safety. Patients with renal impairment: the dose of levetiracetam should be adjusted according to renal function (see SCP). Patients with hepatic impairment: dose adjustment is recommended in patients with severe hepatic impairment (see SPC). 2 SIMILAR MEDICINAL PRODUCTS 2.1 ATC Classification (2005) N N03 N03A N03AX N03AX14 : NERVOUS SYSTEM : ANTIEPILEPTICS : ANTIEPILEPTICS : OTHER ANTIEPILEPTICS : Levetiracetam 2.2 Medicines in the same therapeutic category Not applicable 2.3 Medicines with a similar therapeutic aim Antiepileptics indicated in children in the treatment of partial-onset seizures with or without secondary generalisation: Only in combination with other antiepileptics - Gabapentin - Neurontin and generic versions 600 mg, 800 mg, film-coated tablets, and Neurontin 100 mg, capsules (in children from the age of 3 years) 3
4 - Tiagabine - Gabitril 5 mg, 10 mg, and 15 mg, scored film-coated tablets (in adolescents over the age of 12 years) - Lamotrigine - Lamictal and generic versions, 5 mg, 25 mg, 50 mg, 100 mg and 200 mg, dispersible or chewable tablets and Lamictal 2 mg, dispersible tablets (in children 2 years or older) Existing medicinal product in the form of oral solution: - Vigabatrin - Sabril 500 mg, film-coated tablets and Sabril 500 mg, granulate for oral solution (in infants and children, only as a last resort) As a first- or second-line monotherapy and as add-on therapy - Phenobarbital - Gardenal 10 mg, 50 mg and 100 mg, tablets (in infants and children) - Phenytoin - Di-Hydan 100 mg, scored tablets (in infants and children) - Primidone - Mysoline 250 mg, scored tablets (in infants and children) - Topiramate - Epitomax 50 mg, 100 mg, and 200 mg, film-coated tablets (only as secondline therapy in children 2 years old and over) - Medicinal products in an oral solution form: Carbamazepine - Tegretol 100 mg/5 ml, oral suspension, Tegretol 200 mg, scored tablets and Tegretol SR 200 mg and 400 mg, filmcoated tablets (in infants and children) - Valproic acid - Depakine 200 mg and 500 mg, gastro-resistant tablets, Depakine mg/ml, syrup, Depakine 200 mg/ml, oral solution and Depakine Chrono 500 mg, SR tablets (in infants and children) - Oxcarbazepine - Trileptal 150 mg, 300 mg, 600 mg, film-coated tablets and Trileptal 60 mg/ml, oral suspension (in children aged 6 years and over) Injected forms: - Valproic acid - Depakine 400 mg/4 ml, preparation for intravenous injection (in infants and children) - Phosphenytoin - Prodilantin 75 mg/ml, solution for injection (in children aged 5 years and over) - Phenobarbital - Gardenal 40 mg/2 ml and 200 mg/4 ml, injected forms (in infants and children 3 ANALYSIS OF AVAILABLE DATA Keppra, oral forms The data submitted by the company consist of studies carried out in children: - 2 pharmacokinetic studies, not discussed in the rest of this Opinion, - 1 phase III trial comparing levetiracetam with placebo (N159), - 1 study of long-term safety. Keppra, injected form No data on efficacy and safety in children have been submitted. 4
5 3.2 Efficacy Trial N159 1,2,3 This randomised, placebo-controlled, double-blind, phase III trial evaluated the efficacy and tolerability of levetiracetam as add-on therapy with one or two antiepileptics in the treatment of treatment-resistant partial-onset seizures in children aged 4 16 years. Trial design The trial lasted 28 weeks. The dose of levetiracetam used was 20 mg/kg/day for 2 weeks, followed by 40 mg/kg/day for 2 weeks (titration period). If this was well tolerated, 60 mg/kg/day were given for 10 weeks (evaluation period). Inclusion criteria Children aged 4 16 years: - having partial-onset seizures, with or without secondary generalisation, not controlled by antiepileptic therapy, - having at least 4 seizures a week before randomisation, - treated with a maximum of 2 antiepileptics at inclusion (intermittent prescription of benzodiazepine was permitted as a third antiepileptic. If benzodiazepine was prescribed regularly, it was classed as one of the two antiepileptics). Endpoints - The primary endpoint was frequency of seizures per week during the treatment period (14 weeks). - Secondary endpoints included the proportion of responders (percentage of patients with a decrease of more than 50% in number of seizures per week compared with baseline) and the percentage of seizure-free patients from the start of the evaluation period. The intent-to-treat (ITT) population was analysed. Results patients included - ITT population: n = 198 (placebo: n = 97, levetiracetam: n = 101) - At inclusion, all patients were treated with at least one antiepileptic: 30.7% of children in the levetiracetam group were treated with a single antiepileptic, compared with 37.1% in the placebo group, 60.4% in the levetiracetam group were treated with two antiepileptics, compared with 55.7% in the placebo group, 8.9% of children in the levetiracetam group were also treated with a benzodiazepine, compared with 7.2% in the placebo group. 1 Evaluation of the efficacy and tolerability of levetiracetam add-on treatment in refractory pediatric patients with partial onset seizures: a 28-week double-blind, placebo-controlled multi-center trial. RRCE04E2401 Trial N159 2 Glauser, Gauer, Chen, and LEV N159 pediatric study group. Multicenter, double-blind, placebo-controlled trial of add-on levetiracetam (Keppra ) therapy (up to 60 mg/kg/day) in pediatric patients with refractory partial epilepsy. Epilepsia 2004; 45 Suppl 7: Glauser TA et al. Double-blind placebo-controlled trial of add-on levetiracetam in pediatric partial seizures. Neurology, (1 of 2) 2006:
6 Patient characteristics Levetiracetam (n = 101) Placebo (n = 97) Median age (years) Most common concomitant antiepileptics (%) Carbamazepine Topiramate Valproate Lamotrigine Oxcarbazepine Median number of seizures/week Statistical analysis (Kruskal-Wallis test) showed that the reduction in frequency of weekly seizures with levetiracetam (-1.6 seizures) was greater than that observed with placebo (-0.7 seizure). There was a higher percentage of responders in the levetiracetam group than in the placebo group: % (45 patients) in the levetiracetam group, % (19 patients) in the placebo group, Seven patients in the levetiracetam group were seizure-free compared with 1 patient in the placebo group. 3.3 Undesirable effects In the studies submitted in the dossier, the safety profile of levetiracetam (tablet form) in children was the same as that for adults. Trial N159 Frequency of main undesirable events during treatment (%) Levetiracetam Placebo Infection Drowsiness Accidental injuries Vomiting Headache Five patients treated with levetiracetam discontinued treatment because of adverse events compared with nine patients in the placebo group. 55.4% patients in the levetiracetam group reported adverse events possibly related to treatment compared with 40.2% in the placebo group. 6
7 Open-label study of long-term safety This study was carried out in 223 children, 139 of whom had already received levetiracetam for between 6 and 14 weeks. Mean follow-up was 18 months. Overall, 97% of the children (216/223) experienced at least one adverse event during the treatment period. The most common adverse events were: - infection 52.0% - fever 24.7% - accidental injury 21.1% - headache 21.1% - otitis media 21.1% - drowsiness 20.6% - pharyngitis 20.6% 11 children discontinued treatment with levetiracetam because of an adverse event. The dosage was reduced in 50 children. According to PSUR [Periodic Safety Update Report] data from 30 November 1999 to 31 August 2004, the main adverse events reported in children (aged 1 month to 16 years) treated with levetiracetam were psychiatric disorders (29%) and neurological disorders (17%). One case of suicide was reported. 3.4 Conclusion The results of trial N159 showed that weekly frequency of partial-onset seizures decreased by -1.6 seizures in patients treated with levetiracetam compared with -0.7 seizures in patients treated with placebo. The profile of adverse events reported during the treatment period was the same for both groups. The main adverse events reported with levetiracetam were neurological and mental disorders. 4 TRANSPARENCY COMMITTEE CONCLUSIONS 4.1 Actual benefit Epileptic seizures are symptoms of a very wide range of heterogeneous disorders. Epilepsy is defined as the spontaneous medium and long-term seizure repetition. It can cause marked deterioration in the patient's quality of life. In children, epilepsy and its treatment can have major repercussions on the different stages of cognitive, behaviour and social acquisition. These drugs are given as preventive therapy. They are second-line drugs. The efficacy/undesirable effects ratio is high. Alternative drugs are available. 7
8 Public health benefit Burden of the disease Public health need Anticipated impact of Keppra in this indication Conclusion Partial epilepsy is a common disorder. Repeated seizures in some patients are likely to cause marked deterioration in quality of life. Overall, partial epilepsy is a moderate burden on public health. The burden corresponding to the population of children suffering from partial epilepsy after failure of monotherapy is small because of the small number of patients concerned. There is a need because pharmacoresistant partial epilepsy is still common and causes major incapacity. The need is particularly marked in children as there are few treatment options. It cannot be quantified. One may assume that Keppra will have an impact on morbidity (including quality of life) but this has not yet been verified in real-life practice. At population scale, this impact can only be small and it is not guaranteed. Making Keppra available should therefore provide a partial response to the identified need. In the current state of knowledge and taking account of the other drugs currently available, a public health benefit is expected for Keppra. This benefit is minor. The level of actual benefit for these medicinal products is substantial. 4.2 Improvement in actual benefit Keppra in oral form contributes a level III improvement in actual benefit in the extended indication in view of the low risk of pharmacokinetic interactions with levetiracetam and the lack of pharmaceutically appropriate third-generation antiepileptics for use in children, Keppra 100 mg/ml oral solution, an addition to the current Keppra range of 250 mg, 500 mg and 100 mg film-coated tablets, does not contribute any improvement in actual benefit (level V) in adults. Keppra 100 mg/ml concentrate for infusion contributes a level IV improvement in actual benefit in this indication in view of the absence of injected formulations of thirdgeneration antiepileptics. 4.3 Therapeutic use 4 The 2004 French consensus conference established that the management strategy for pharmacoresistant partial epilepsy in adults also applied to children, with features.. First-line drugs recommended as monotherapy are carbamazepine or valproic acid because their benefit-risk ratio is better than that of phenytoin and phenobarbital (Grade C recommendation). 4 Fédération Française de Neurologie (FFN) and the Ligue Française contre l Epilepsie (LFCE). Proceedings of a consensus conference, Prise en charge des épilepsies partielles pharmaco-résistantes [Management of drugresistant partial epilepsy]. ANAES, March
9 Monotherapy should use optimum-dose carbamazepine at least once (expert panel opinion). Carbamazepine should be prescribed with caution in children because of the risks of exacerbation of some types of epilepsy. Unlike in adults, vigabatrin could be used to treat drug-resistant partial epilepsy in infants, but its prescription remains restricted because of the risk of onset of irreversible visual field constriction (AFSSAPS press release, September 2002). Among the new antiepileptics, lamotrigine was the subject of a pharmacovigilance information letter to prescribers (December 2005) because of serious dermatologic adverse events, mainly toxic epidermal necrolysis. Combination therapy should only be used at least after monotherapy has failed at least twice. There are insufficient data to support any particular combination of drugs. Prescription of the combination valproate-lamotrigine is governed by specific rules because of the risk of dermatologic toxicity from lamotrigine. The combination of two antiepileptics chosen should ideally include antiepileptics which are not enzyme inducers, which are rapidly titrated, and which avoid the need for a lunchtime midday dose. Combinations of more than two antiepileptic drugs are not recommended. If one or more forms of combination therapy fail, epilepsy and its treatment should be reassessed at a specialist centre. An injected form is recommended in acute symptomatic epileptic seizures if an injected benzodiazepine is inappropriate. In addition, it is an alternative pharmaceutical form when the oral route cannot be used. 4.4 Target population Keppra is indicated as add-on therapy in children aged 4 years or over with epilepsy, in the treatment of partial-onset seizures with or without secondary generalisation. The target population for Keppra has been estimated from the following data [INSEE, 2005 demographic data; ANAES 2004]: - Number of children aged 4 16 (January 1, 2006): Prevalence of epilepsy: Frequency of cases of partial-onset seizures: 60% - Effectiveness of monotherapy about 70-80% of cases Add-on therapy with Keppra will be indicated in about 20-30% of these cases. The number of children likely to be given Keppra as add-on therapy after failure of monotherapy would therefore be between 5840 and Transparency Committee recommendations The Committee recommended inclusion on the list of medicines reimbursed by National Insurance and on the list of medicines approved for use by hospitals and various public services of Keppra 250 mg, 500 mg and 1000 mg, film-coated tablets in the extended indication of children aged 4 years and over. The Committee recommended inclusion on the list of medicines reimbursed by National Insurance of Keppra 100 mg/ml oral solution and on the list of medicines approved for use by hospitals and various public services of Keppra 100 mg/ml oral solution and of Keppra 100 mg/ml concentrate for infusion in the indication. 9
10 The Transparency Committee asked for the long-term study currently in progress to monitor adults treated with Keppra to be extended to children. This study should make it possible to: - establish the profile of patients treated (sociodemographic data, history, diagnosis by a specialist in epilepsy, concomitant disorders, etc), - establish prescribing rules (indication, dosage, concomitant prescription, etc) and a treatment strategy, - confirm that Keppra is effective in real-life practice using criteria yet to be defined by the Scientific Committee. The study duration should be established by an independent scientific committee, based on evidence, and should be sufficient to satisfy the Committee's request Packaging: Suitable for the prescription conditions Reimbursement rate: 65% 10
Opinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationTRANSPARENCY COMMITTEE Opinion 02 April 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 02 April 2014 TROBALT 50 mg, film-coated tablets B/21 (CIP: 34009 417 163 2 4) B/84 (CIP: 34009 417 164 9 2) TROBALT
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationTRANSPARENCY COMMITTEE. Opinion. 6 June 2007
TRANSPARENCY COMMITTEE Opinion 6 June 2007 DIACOMIT 250 mg, capsule-container (PP) B/ 60 (CIP: 378 322-1) DIACOMIT 500 mg, capsule-container (PP) B/ 60 (CIP: 378 325-0) DIACOMIT 250 mg, powder for oral
More informationTRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 LYRICA 25 mg capsules Pack of 56 capsules (CIP: 365 127-0) Pack of 84 capsules (CIP: 365 135-3) Pack of
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 December 2007 METHADONE AP-HP 1mg, gelatin-coated capsule Box of 7 (CIP: 379 146-2) METHADONE AP-HP 5mg, gelatin-coated
More informationANTIEPILEPTIC Medicines
ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lacosamide (Vimpat) Reference Number: CP.PMN.155 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationAntiepileptics. Medications Comment Quantity Limit Carbamazepine. May be subject Preferred to quantity limit Epitol
Market DC Antiepileptics Override(s) Approval Duration Prior Authorization 1 year Step Therapy Quantity Limit *Indiana Medicaid See State Specific Mandate below *Maryland Medicaid See State Specific Mandate
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationTRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 TEMERIT DUO 5 mg/12.5 mg, film-coated tablets Pack of 30 (CIP: 393 976-9) Pack of 90 (CIP: 393 977-5)
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationPrescribing and Monitoring Anti-Epileptic Drugs
Prescribing and Monitoring Anti-Epileptic Drugs Mark Granner, MD Clinical Professor and Vice Chair for Clinical Programs Director, Iowa Comprehensive Epilepsy Program Department of Neurology University
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 January 2007 DICLOFENAC SODIUM MIKA PHARMA 4%, skin spray solution 7.5 g Vial (CIP: 362 261-8) 12.5 g Vial (CIP:
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 RELISTOR 12 mg/0.6 ml solution for injection 1 vial (CIP: 387 365-1) 2 vials + 2 sterile syringes
More informationTransparency Committee Opinion 8 January 2014
The legally binding text is the original French version Transparency Committee Opinion 8 January 2014 RHINOTROPHYL, nasal spray, solution Vial of 20 ml (CIP: 34009 309 102 6 9) Applicant: JOLLY-JATEL INN
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of
More informationTRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 MERONEM 1 g, powder for solution for IV Injection Box of 10 vials (CIP: 387 830-6) Applicant: ASTRAZENECA
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 Review of the dossier of the proprietary drugs included on the list of reimbursable medicines for a
More informationClinical Policy: Clobazam (Onfi) Reference Number: CP.PMN.54 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Onfi) Reference Number: CP.PMN.54 Effective Date: 11.01.12 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationRefractory epilepsy: treatment with new antiepileptic drugs
Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 VOTUBIA 2.5 mg, tablet B/30 (CIP code: 219 475-8) VOTUBIA 5 mg, tablet B/30 (CIP code: 219 476-4) Applicant:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 SEGLOR 5 mg, hard capsule B/30 (CIP code: 321 899-8) SEGLOR LYOC 5 mg, oral lyophilisate B/30 (CIP code:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More information2018 American Academy of Neurology
Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the
More informationEfficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials
Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationNew Medicines Profile
New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)
More informationTRANSPARENCY COMMITTEE OPINION. 13 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 January 2010 XOLAIR 150 mg, powder and solvent for solution for injection Box containing 1 x 150 mg vial + 1 x
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 TAMIK Ge 3 mg, soft capsule B/60 (CIP code: 322 714-1) Applicant: IPRAD dihydroergotamine mesylate ATC
More informationCanadian Expert Drug Advisory Committee Final Recommendation Plain Language Version
Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version LACOSAMIDE (Vimpat UCB Canada Inc.) Indication: Epilepsy, Partial-Onset Seizures Recommendation: The Canadian Expert
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 EXFORGE HCT 5 mg/160 mg/12.5 mg, film-coated tablets B/30 (CIP code: 397 327-5) B/56 (CIP code: 397
More informationAntiepileptic Drugs (Anticonvulsants )
Antiepileptic Drugs (Anticonvulsants ) NEPHAR 305 Pharmaceutical Chemistry I Assist.Prof.Dr. Banu Keşanlı 1 Anticonvulsants Anticonvulsants, sometimes also called antiepileptics, belong to a diverse group
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationTable A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents
Table A: Summary of FDA and European Commission Guidance for Industry for Adverse Drug Reaction reporting in product information documents Food and Drug Administration. Guidance for Industry Adverse Reactions
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 February 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 February 2010 ADIXONE 50 µg, tablet Box of 30 (CIP: 390 604.3) Box of 60 (CIP: 390 606.6) Box of 90 (CIP: 390 607.2)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 IKARAN LP 5 mg, tablets B/30 (CIP: 339 287-4) IKARAN Ge 2 mg/ml, oral solution in drops Vial of 50 ml
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationDrug Monograph-Oxcarbazepine
Drug Monograph Generic name: Oxcarbazepine Brand name: Trileptal Manufacturer: Norvatis (www.norvatis.com) Classification: Anti-epileptic drug Similar agents: Carbamazepine Summary Oxcarbazepine is a new
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: May 2009 LMT:2PI
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 OKIMUS, coated tablets B/2 blister strips of 20 tablets (CIP code: 363 666-1) Applicant: BIOCODEX Quinine
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationObjectives / Learning Targets: The learner who successfully completes this lesson will be able to demonstrate understanding of the following concepts:
Boone County Fire District EMS Education-Paramedic Program EMS 270 Medical Cases-Seizures Resources Seizures screencast Seizures Flowchart and Seizures Flowchart Video Explanation Objectives / Learning
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationAPPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline
Drug name APPENDIX T - Unit costs of anti-epileptic drugs for 2012 guideline Unit costs and weighted average unit costs for drug used in the treatment of focal and generalised epilepsies Prescription Cost
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 RECTOGESIC 4 mg/g, rectal ointment B/1 (CIP 376 537-0) Applicant : PROSTRAKAN PHARMA SAS Glyceryl trinitrate
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationNEW ZEALAND DATA SHEET
1 PRODUCT NAME LEVETIRACETAM-AFT Oral Solution 100mg/mL LEVETIRACETAM-AFT Concentrate Solution for IV Infusion 500mg/5mL QUALITATIVE AND QUANTITATIVE COMPOSITION Every bottle LEVETIRACETAM-AFT Oral Solution
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationeslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd
eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationLondon, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION
London, 07 August 2006 Product name: Keppra Procedure No. EMEA/H/C/277/II/63 SCIENTIFIC DISCUSSION 1/15 EMEA 2006 1. Introduction Epilepsy is one of the most common and challenging neurological disorders.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Oxcarbazepine (Trileptal ) for the treatment of epilepsy LMMG Recommendation: Amber 0: Oxcarbazepine (Trileptal ) is recommended for use as monotherapy or adjunctive therapy
More informationRECENT MAJOR CHANGES Warnings and Precautions, Hemophagocytic
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationDisclosure. Learning Objectives
Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the
More informationAUSTRALIAN PRODUCT INFORMATION KEPPRA (LEVETIRACETAM) FILM-COATED TABLETS AND ORAL SOLUTION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION KEPPRA (LEVETIRACETAM) FILM-COATED TABLETS AND ORAL SOLUTION 1 NAME OF THE MEDICINE Levetiracetam QUALITATIVE AND QUANTITATIVE COMPOSITION Keppra film-coated tablets are
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3001-11 Program Step Therapy - Anticonvulsants Medication/Therapeutic Class Anticonvulsants Depakote, Depakote ER, Felbatol, Keppra,
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 12 September 2007 INFRACYANINE 25 mg/10 ml, powder and solvent for solution for injection 25 mg vial with one 10 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Keppra 250 mg film-coated tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 250 mg levetiracetam.
More informationNew Patient Questionnaire - Epilepsy
New Patient Questionnaire - Epilepsy Person completing this form: (if other than the patient) GENERAL SEIZURE HISTORY Relationship: When do you think your child had their first seizure? When was the last
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 Examination of the dossier for a medicinal product included for a 5-year period starting on 7 January
More informationNew Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Absence seizures, 6 in childhood, 95 Adults, seizures and status epilepticus in, management of, 34 35 with first-time seizures. See Seizure(s),
More informationThe limited submission criteria were met based on a minor licence extension and anticipated minimal budgetary impact in NHS Wales
AWMSG Secretariat Assessment Report Limited submission Brivaracetam (Briviact ) 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets; 10 mg/ml oral solution; 10 mg/ml solution for injection/infusion
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 April 2011 Review of the dossier for a proprietary medicinal product listed for a limited duration in accordance
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN 2 RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERISE THE RISKS
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for Briviact This is a summary of the risk management plan (RMP) for Briviact. The RMP details important risks of Briviact,
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 September 2007 RELENZA 5mg/dose, inhalation powder, in single-dose containers 20 single-dose containers with an
More informationLAMICTAL GlaxoSmithKline
LAMICTAL GlaxoSmithKline Lamotrigine QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets: LAMICTAL, 25, 50, 100 and 200 mg. Dispersible/Chewable Tablets: LAMICTAL, 2, 5, 25, 50, 100 and 200 mg. PHARMACEUTICAL
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationKeppra Film-coated Tablets 500mg
Keppra Film-coated Tablets 500mg NAME OF THE MEDICINAL PRODUCT Levetiracetam 500 mg film-coated tablets. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg levetiracetam.
More informationThe legally binding text is the original French version. Opinion 28 May Hospital use (French Social Security Code L )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 ADASUVE 9.1 mg, inhalation powder, pre-dispensed B/5 (CIP: 3400958597671) Applicant: BIOPROJET PHARMA
More informationDOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 100 mg, 150 mg, and 200 mg; scored. (3.1, 16)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
More information